<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649946</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-14-005</org_study_id>
    <nct_id>NCT02649946</nct_id>
  </id_info>
  <brief_title>Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft</brief_title>
  <acronym>AVeNEW</acronym>
  <official_title>A Prospective, Multi-Center, Randomized, Concurrently-Controlled Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AVeNEW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular&#xD;
      Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of&#xD;
      the Arteriovenous (AV) access circuit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the use of the COVERA™ Vascular Covered Stent (following percutaneous&#xD;
      transluminal angioplasty (PTA)) to PTA alone for the treatment of stenotic lesions in the&#xD;
      upper extremity venous outflow of the arteriovenous (AV) access circuit of subjects dialyzing&#xD;
      with an AV fistula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP)</measure>
    <time_frame>6 months post index procedure</time_frame>
    <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at, or adjacent to,the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area. COVERA Vascular Covered Stent (following PTA) is evaluated against subjects treated PTA alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events</measure>
    <time_frame>30 days post index procedure</time_frame>
    <description>Safety is defined as freedom from any adverse event(s) (AEs), localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Target Lesion Primary Patency (TLPP) at 12 Months Post Index Procedure</measure>
    <time_frame>12 months post-index procedure</time_frame>
    <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Access Circuit Primary Patency (ACPP).</measure>
    <time_frame>6 months post index procedure</time_frame>
    <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
ACPP ends with a reintervention anywhere within the access circuit. Vessel rupture caused by PTA is not an ACPP failure unless achieving hemostasis also causes thrombosis.&#xD;
Testing of this secondary endpoint is performed in a hierarchical fashion. Thus, In order to perform hypothesis test of ACPP at 6-month, TLPP at 12-months must be successful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Primary Patency (TLPP)</measure>
    <time_frame>1, 3, 18 and 24 months post index procedure</time_frame>
    <description>Defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access.&#xD;
mITT subjects results are presented. N= number of subjects in the mITT Population with evaluable data. Evaluation through 1, 3, 18 and 24 months post index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Access Circuit Primary Patency (ACPP)</measure>
    <time_frame>1, 3, 12, 18, and 24 months post index procedure</time_frame>
    <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
N = number of subjects in the mITT Population with evaluable data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Free From Device and Procedure Related AEs Involving the AV Access Circuit</measure>
    <time_frame>Evaluation through 1, 3, 6, 12, 18, and 24 months post-index procedure</time_frame>
    <description>Number of Participants Free from Device and Procedure Related AEs Involving the AV Access Circuit (ITT population).&#xD;
Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
The relationships with device/procedure of the events are based on CEC adjudications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Arteriovenous (AV) Access Circuit Reinterventions</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
    <description>Defined as the number of reinterventions to the AV access circuit until access abandonment or through study completion.&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
MITT results are presented for this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Target Lesion Reinterventions</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
    <description>Total Number of Target Lesion Reinterventions defined as the number of reinterventions to maintain target lesion patency (mITT subjects).&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index of Patency Function (IPF)</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
    <description>IPF is defined as the time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis. A visit is defined as one (1) procedural event, regardless of the number or type of interventions performed during the visit. The index procedure is counted as the first visit to ensure all subjects have a denominator of at least one.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.&#xD;
The IPF is representative of the number of days between interventions to maintain access circuit patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.&#xD;
mITT results are analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index of Patency Function - Target Lesion (IPF-T)</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
    <description>IPF-T (Index of Patency Function - Target Lesion) is defined as the time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12, 18 and 24 months.&#xD;
The IPF for target lesion patency is representative of the approximate (mean) number of days between interventions to maintain target lesion patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-intervention Secondary Patency</measure>
    <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
    <description>Secondary Patency is defined as the interval after the index intervention until the access is abandoned. Multiple repetitive treatments can be included in post-intervention secondary patency.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
mITT subjects results are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Technical Success</measure>
    <time_frame>On Day of Index Procedure</time_frame>
    <description>Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure. Therefore, for this measure, only COVERA data are relevant.&#xD;
mITT results are presented. Number of participants (n) included in this analysis is different from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
Technical success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Procedure Success</measure>
    <time_frame>On Day of Index Procedure</time_frame>
    <description>Procedure Success is defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis.&#xD;
Procedure success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Stenosis</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Covera Vascular Covered Stent following PTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA only using uncoated PTA Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Covera Vascular Covered Stent following PTA</intervention_name>
    <description>Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
    <arm_group_label>Covera Vascular Covered Stent following PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon</intervention_name>
    <description>Treatment of stenoses with PTA only</description>
    <arm_group_label>PTA only using uncoated PTA Balloon</arm_group_label>
    <other_name>Standard Balloon Angioplasty (POBA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria:&#xD;
&#xD;
          -  Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to&#xD;
             collection of study data or performance of study procedures.&#xD;
&#xD;
          -  Subject must be either a male or non-pregnant female ≥ 21 years of age with an&#xD;
             expected lifespan sufficient to allow for completion of all study procedures.&#xD;
&#xD;
          -  Subject must be willing to comply with the protocol requirements, including the&#xD;
             clinical and telephone follow-up.&#xD;
&#xD;
          -  Subject must have an upper extremity arteriovenous (AV) fistula that has undergone at&#xD;
             least one successful dialysis session with two-needle cannulation, prior to the index&#xD;
             procedure.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have angiographic evidence of a stenosis ≥ 50% (by visual estimation)&#xD;
             located in the venous outflow of the AV access circuit and present with clinical or&#xD;
             hemodynamic evidence of AV fistula dysfunction.&#xD;
&#xD;
          -  The target lesion must be ≤ 9cm in length. Note: multiple stenoses may exist within&#xD;
             the target lesion.&#xD;
&#xD;
          -  The reference vessel diameter of the adjacent non-stenotic vein must be between 5.0&#xD;
             and 9.0mm.&#xD;
&#xD;
        Clinical Exclusion Criteria:&#xD;
&#xD;
          -  The subject is dialyzing with an AV graft.&#xD;
&#xD;
          -  The target lesion has had a corresponding thrombosis treated within 7 days prior to&#xD;
             the index procedure.&#xD;
&#xD;
          -  The hemodialysis access is located in the lower extremity.&#xD;
&#xD;
          -  The subject has an infected AV fistula or uncontrolled systemic infection.&#xD;
&#xD;
          -  The subject has a known uncontrolled blood coagulation/bleeding disorder.&#xD;
&#xD;
          -  The subject has a known allergy or hypersensitivity to contrast media which cannot be&#xD;
             adequately pre-medicated.&#xD;
&#xD;
          -  The subject has a known hypersensitivity to nickel-titanium (Nitinol) or tantalum.&#xD;
&#xD;
          -  The subject has another medical condition, which, in the opinion of the Investigator,&#xD;
             may cause him/her to be non-compliant with the protocol, confound the data&#xD;
             interpretation, or is associated with a life expectancy insufficient to allow for the&#xD;
             completion of study procedures and follow-up.&#xD;
&#xD;
          -  The subject is currently participating in an investigational drug or another device&#xD;
             study that has not completed the study treatment or that clinically interferes with&#xD;
             the study endpoints. Note: Studies requiring extended follow-up visits for products&#xD;
             that were investigational, but have since become commercially available, are not&#xD;
             considered investigational studies.&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          -  Additional stenotic lesions (≥ 50%) in the venous outflow that are &gt; 3cm from the edge&#xD;
             of the target lesion and are not successfully treated (defined as &lt; 30% residual&#xD;
             stenosis) prior to treating the target lesion.&#xD;
&#xD;
          -  An aneurysm or pseudoaneurysm is present within the target lesion.&#xD;
&#xD;
          -  The location of the target lesion would require the COVERA™ Vascular Covered Stent be&#xD;
             deployed across the elbow joint.&#xD;
&#xD;
          -  The target lesion is located within a stent.&#xD;
&#xD;
          -  The location of the target lesion would require that the COVERA™ Vascular Covered&#xD;
             Stent be deployed at or across the segment of fistula utilized for dialysis needle&#xD;
             puncture (i.e., &quot;cannulation zone&quot;).&#xD;
&#xD;
          -  The location of the target lesion would require that the COVERA™ Vascular Covered&#xD;
             Stent be placed in the central veins (subclavian, brachiocephalic, superior vena cava&#xD;
             (SVC)) or under the clavicle at the thoracic outlet.&#xD;
&#xD;
          -  There is incomplete expansion of an appropriately sized angioplasty balloon to its&#xD;
             expected profile, in the operator's judgment, during primary angioplasty at the target&#xD;
             lesion prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Dolmatch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Palo Alto Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Vascular Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Centers</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology Imaging Associates</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University &amp; Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates, P.A.</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Kidney Group</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Access Care</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal and Transplant Associates of New England, P.C.</name>
      <address>
        <city>West Springfield</city>
        <state>Massachusetts</state>
        <zip>01089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Nephrology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Access Care</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant Vascular Clinic</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Kensington Gardens</city>
        <state>South Australia</state>
        <zip>5068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medish Centrum</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets Spital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <results_first_submitted>March 15, 2019</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2019</results_first_posted>
  <disposition_first_submitted>March 5, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>March 8, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 11, 2019</disposition_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Stenosis</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>AV Fistula</keyword>
  <keyword>Arteriovenous (AV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02649946/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between June 9, 2016, and July 20, 2017, Investigators randomized 280 subjects into the study at 24 sites in the US, Europe, and Australia/New Zealand (50-75% of subjects treated in the US). The final subject completed 6 month follow-up on January 30, 2018. Anticipated data of study completion (last subject, last visit) is Q3, 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Covera Vascular Covered Stent Following PTA</title>
          <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
        </group>
        <group group_id="P2">
          <title>PTA Only Using Uncoated PTA Balloon</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Erroneously enrolled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 6-month follow-up visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Covera Vascular Covered Stent Following PTA</title>
          <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
        </group>
        <group group_id="B2">
          <title>PTA Only Using Uncoated PTA Balloon</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 and &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Island</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Please note that New Zealand sites are included in the Australia section.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <description>Medical history information, including medical risk factors as well as selected medical history background for the ITT population is provided. &quot;Other Disease&quot; category includes Bleeding Disorder, Cancer, Steal Syndrome, and other.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes (Type 1 and 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cigarette Smoking (current or former)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description: Target Limb</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left Arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description: Access Position</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Forearm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Elbow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description:Inflow Artery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Axillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brachial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description: Outflow Vein</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Axillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basilic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cephalic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description: Fistula Configuration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Radiocephalic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brachiocephalic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transposed Brachiobasilic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AV Access Circuit Description: Transposed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP)</title>
        <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at, or adjacent to,the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area. COVERA Vascular Covered Stent (following PTA) is evaluated against subjects treated PTA alone.</description>
        <time_frame>6 months post index procedure</time_frame>
        <population>Number of Participants with Target Lesion Primary Patency. Modified Intended to Treat (mITT) population results were analyzed for this effectiveness endpoint. N = number of subjects in mITT population with evaluable data. Excluded subjects that discontinued, expired and or access abandoned prior to day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP)</title>
          <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at, or adjacent to,the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area. COVERA Vascular Covered Stent (following PTA) is evaluated against subjects treated PTA alone.</description>
          <population>Number of Participants with Target Lesion Primary Patency. Modified Intended to Treat (mITT) population results were analyzed for this effectiveness endpoint. N = number of subjects in mITT population with evaluable data. Excluded subjects that discontinued, expired and or access abandoned prior to day 15.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: The (survival) rate in subjects treated with the COVERA Vascular Covered Stent (following PTA) with respect to TLPP through 6 months is greater than that in subjects treated with PTA alone in the treatment of stenoses in the upper extremity venous outflow of subjects dializing with an AV fistula.&#xD;
Sample size calculation: 238 randomized subjects [214 evaluable] will give 92% power with one-sided type 1 error = 0.025.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>TLPP evaluated at 6 months post-index procedure to assess if TLPP of COVERA is superior to that of PTA alone, by direct comparison.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Test successful if the one-side p-value is less than 0.025 and the result is in favor of the COVERA Vascular Covered Stent.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events</title>
        <description>Safety is defined as freedom from any adverse event(s) (AEs), localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death.</description>
        <time_frame>30 days post index procedure</time_frame>
        <population>Number of Participants Free from Primary Safety Events. All Intended to Treat Subjects (ITT) are included in this analysis. Primary safety endpoint evaluated against standard PTA alone.2 subjects excluded from N COVERA due to discontinuation or death prior to day 23 of follow up. One subject excluded from N PTA arm due to death prior to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events</title>
          <description>Safety is defined as freedom from any adverse event(s) (AEs), localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death.</description>
          <population>Number of Participants Free from Primary Safety Events. All Intended to Treat Subjects (ITT) are included in this analysis. Primary safety endpoint evaluated against standard PTA alone.2 subjects excluded from N COVERA due to discontinuation or death prior to day 23 of follow up. One subject excluded from N PTA arm due to death prior to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: The safety rate in subjects treated with the COVERA Vascular Covered Stent (following PTA) is non-inferior to the safety rate in subjects treated with PTA alone through 30 days in the treatment of stenotic lesions.&#xD;
Sample size: 238 randomized subjects [226 evaluable] will give 85% power with one-sided type 1 error = 0.025.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Farrington and Manning Exact Test is used to test the primary safety hypothesis. The test is successful if the one-sided p-value is less than 0.025.</non_inferiority_desc>
            <p_value>0.0022</p_value>
            <method>Farrington and Manning</method>
            <method_desc>Non-inferiority test with non-inferiority margin of 10%.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Target Lesion Primary Patency (TLPP) at 12 Months Post Index Procedure</title>
        <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area.</description>
        <time_frame>12 months post-index procedure</time_frame>
        <population>Number of Participants with Target Lesion Primary Patency (TLPP). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 12 month follow-up or did not meet endpoint inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Target Lesion Primary Patency (TLPP) at 12 Months Post Index Procedure</title>
          <description>TLPP is defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access. Primary patency ends when any of the following occurs: a) clinically driven reintervention in the treatment area; b) thrombotic occlusion within the treatment area; c) surgical intervention that excludes the original treatment area from the AV circuit, and/or d) abandonment of the AV fistula due to inability to treat the original treatment area.</description>
          <population>Number of Participants with Target Lesion Primary Patency (TLPP). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 12 month follow-up or did not meet endpoint inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Access Circuit Primary Patency (ACPP).</title>
        <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
ACPP ends with a reintervention anywhere within the access circuit. Vessel rupture caused by PTA is not an ACPP failure unless achieving hemostasis also causes thrombosis.&#xD;
Testing of this secondary endpoint is performed in a hierarchical fashion. Thus, In order to perform hypothesis test of ACPP at 6-month, TLPP at 12-months must be successful.</description>
        <time_frame>6 months post index procedure</time_frame>
        <population>Number of Participants with Access Circuit Primary Patency (ACPP). Modified Intended to Treat (mITT) population results were analyzed for this effectiveness endpoint. N = number of subjects in mITT population with evaluable data. Excluded subjects that discontinued, expired and or access abandoned prior to day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Access Circuit Primary Patency (ACPP).</title>
          <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
ACPP ends with a reintervention anywhere within the access circuit. Vessel rupture caused by PTA is not an ACPP failure unless achieving hemostasis also causes thrombosis.&#xD;
Testing of this secondary endpoint is performed in a hierarchical fashion. Thus, In order to perform hypothesis test of ACPP at 6-month, TLPP at 12-months must be successful.</description>
          <population>Number of Participants with Access Circuit Primary Patency (ACPP). Modified Intended to Treat (mITT) population results were analyzed for this effectiveness endpoint. N = number of subjects in mITT population with evaluable data. Excluded subjects that discontinued, expired and or access abandoned prior to day 15.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Primary Patency (TLPP)</title>
        <description>Defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access.&#xD;
mITT subjects results are presented. N= number of subjects in the mITT Population with evaluable data. Evaluation through 1, 3, 18 and 24 months post index procedure.</description>
        <time_frame>1, 3, 18 and 24 months post index procedure</time_frame>
        <population>Number of Participants with Target Lesion Primary Patency (TLPP). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days or 90 days follow-up or did not meet endpoint inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Primary Patency (TLPP)</title>
          <description>Defined as the interval following the index intervention until the next clinically driven reintervention at the original treatment site or until the extremity is abandoned for permanent access.&#xD;
mITT subjects results are presented. N= number of subjects in the mITT Population with evaluable data. Evaluation through 1, 3, 18 and 24 months post index procedure.</description>
          <population>Number of Participants with Target Lesion Primary Patency (TLPP). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days or 90 days follow-up or did not meet endpoint inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLPP at 30-day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLPP at 90-day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLPP at 18 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLPP at 24 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Access Circuit Primary Patency (ACPP)</title>
        <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
N = number of subjects in the mITT Population with evaluable data.</description>
        <time_frame>1, 3, 12, 18, and 24 months post index procedure</time_frame>
        <population>Number of Participants with ACPP by Follow-up Period (mITT subjects). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days and 90 days follow-up or did not meet endpoint inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Access Circuit Primary Patency (ACPP)</title>
          <description>ACPP is defined as the interval following the index intervention until the next access thrombosis or repeated intervention.&#xD;
N = number of subjects in the mITT Population with evaluable data.</description>
          <population>Number of Participants with ACPP by Follow-up Period (mITT subjects). Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days and 90 days follow-up or did not meet endpoint inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACPP at 30-day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPP at 90-day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPP at 12-month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPP at 18 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPP at 24 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Free From Device and Procedure Related AEs Involving the AV Access Circuit</title>
        <description>Number of Participants Free from Device and Procedure Related AEs Involving the AV Access Circuit (ITT population).&#xD;
Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
The relationships with device/procedure of the events are based on CEC adjudications.</description>
        <time_frame>Evaluation through 1, 3, 6, 12, 18, and 24 months post-index procedure</time_frame>
        <population>Number of Participants Free from Device and Procedure (DP) Related AEs Involving the AV Access Circuit (ITT subjects).&#xD;
Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Free From Device and Procedure Related AEs Involving the AV Access Circuit</title>
          <description>Number of Participants Free from Device and Procedure Related AEs Involving the AV Access Circuit (ITT population).&#xD;
Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
The relationships with device/procedure of the events are based on CEC adjudications.</description>
          <population>Number of Participants Free from Device and Procedure (DP) Related AEs Involving the AV Access Circuit (ITT subjects).&#xD;
Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DP AEs Free at 30 day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DP AEs Free at 90 day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DP AEs Free at 6 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DP AEs Free at 12 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DP AEs Free at 18 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DP AEs Free at 24 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Arteriovenous (AV) Access Circuit Reinterventions</title>
        <description>Defined as the number of reinterventions to the AV access circuit until access abandonment or through study completion.&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
MITT results are presented for this analysis.</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
        <population>The (n) in each follow-up periods vary from overall enrollment (N) as some subjects discontinued participation before each follow-up or did not meet endpoint inclusion criteria.&#xD;
The total number of Reinterventions by Follow-Up Period was analyzed as opposed to the number of subjects with at least one AV Access Circuit Reintervention -mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Arteriovenous (AV) Access Circuit Reinterventions</title>
          <description>Defined as the number of reinterventions to the AV access circuit until access abandonment or through study completion.&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
MITT results are presented for this analysis.</description>
          <population>The (n) in each follow-up periods vary from overall enrollment (N) as some subjects discontinued participation before each follow-up or did not meet endpoint inclusion criteria.&#xD;
The total number of Reinterventions by Follow-Up Period was analyzed as opposed to the number of subjects with at least one AV Access Circuit Reintervention -mITT subjects</population>
          <units>AV Access Circuit Reinterventions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AV Access Circuit Reinterventions at 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AV Access Circuit Reinterventions at 90 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AV Access Circuit Reinterventions at 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AV Access Circuit Reinterventions at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AV Access Circuit Reinterventions at 18 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AV Access Circuit Reinterventions at 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Target Lesion Reinterventions</title>
        <description>Total Number of Target Lesion Reinterventions defined as the number of reinterventions to maintain target lesion patency (mITT subjects).&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
        <population>The (n) in each follow-up periods vary from overall enrollment (N) as some subjects discontinued participation before each follow-up or did not meet endpoint inclusion criteria.&#xD;
The total number of Target Lesion Reinterventions by Follow-Up Period was analyzed as opposed to the number of subjects with at least one AV Target Lesion Reintervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Target Lesion Reinterventions</title>
          <description>Total Number of Target Lesion Reinterventions defined as the number of reinterventions to maintain target lesion patency (mITT subjects).&#xD;
Whereas the outcome measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.</description>
          <population>The (n) in each follow-up periods vary from overall enrollment (N) as some subjects discontinued participation before each follow-up or did not meet endpoint inclusion criteria.&#xD;
The total number of Target Lesion Reinterventions by Follow-Up Period was analyzed as opposed to the number of subjects with at least one AV Target Lesion Reintervention.</population>
          <units>Target Lesion Reinterventions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Target Lesion Reinterventions at 30 day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Reinterventions at 90 day Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Reinterventions 6 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Reinterventions at 12 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Reintervention at 18 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Reintervention at 24 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index of Patency Function (IPF)</title>
        <description>IPF is defined as the time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis. A visit is defined as one (1) procedural event, regardless of the number or type of interventions performed during the visit. The index procedure is counted as the first visit to ensure all subjects have a denominator of at least one.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.&#xD;
The IPF is representative of the number of days between interventions to maintain access circuit patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.&#xD;
mITT results are analyzed.</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
        <population>Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 3 months and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
mITT subjects results are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Patency Function (IPF)</title>
          <description>IPF is defined as the time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis. A visit is defined as one (1) procedural event, regardless of the number or type of interventions performed during the visit. The index procedure is counted as the first visit to ensure all subjects have a denominator of at least one.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months.&#xD;
The IPF is representative of the number of days between interventions to maintain access circuit patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.&#xD;
mITT results are analyzed.</description>
          <population>Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 3 months and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
mITT subjects results are presented.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Index of Patency at 30 days Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.22" spread="3.420"/>
                    <measurement group_id="O2" value="29.28" spread="3.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index of Patency at 90 days Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.41" spread="20.511"/>
                    <measurement group_id="O2" value="78.98" spread="20.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index of Patency at 6 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.06" spread="54.449"/>
                    <measurement group_id="O2" value="116.11" spread="53.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index of Patency at 12 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.04" spread="108.690"/>
                    <measurement group_id="O2" value="146.09" spread="89.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index of Patency at 18 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.31" spread="145.278"/>
                    <measurement group_id="O2" value="175.70" spread="125.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index of Patency at 24 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.45" spread="178.916"/>
                    <measurement group_id="O2" value="180.59" spread="135.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index of Patency Function - Target Lesion (IPF-T)</title>
        <description>IPF-T (Index of Patency Function - Target Lesion) is defined as the time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12, 18 and 24 months.&#xD;
The IPF for target lesion patency is representative of the approximate (mean) number of days between interventions to maintain target lesion patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
        <population>Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 3 months and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
mITT subjects results are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Patency Function - Target Lesion (IPF-T)</title>
          <description>IPF-T (Index of Patency Function - Target Lesion) is defined as the time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12, 18 and 24 months.&#xD;
The IPF for target lesion patency is representative of the approximate (mean) number of days between interventions to maintain target lesion patency. Higher values represent a better outcome, that is, more time elapsed between the Index study procedure and reinterventions.</description>
          <population>Number of participants (n) in each follow-up periods varies from overall enrollment (N) as some subjects discontinued participation before the 30 days, 3 months and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
mITT subjects results are presented.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPTF-T at 30 days Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.44" spread="2.958"/>
                    <measurement group_id="O2" value="29.64" spread="2.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPTF-T at 90 days Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.15" spread="15.349"/>
                    <measurement group_id="O2" value="81.35" spread="18.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPTF-T at 6 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.32" spread="43.724"/>
                    <measurement group_id="O2" value="121.75" spread="51.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPTF-T at 12 month Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.32" spread="115.626"/>
                    <measurement group_id="O2" value="160.37" spread="87.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPTF-T at 18 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.24" spread="179.651"/>
                    <measurement group_id="O2" value="200.64" spread="130.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPTF-T at 24 month Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.40" spread="249.548"/>
                    <measurement group_id="O2" value="217.57" spread="158.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-intervention Secondary Patency</title>
        <description>Secondary Patency is defined as the interval after the index intervention until the access is abandoned. Multiple repetitive treatments can be included in post-intervention secondary patency.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
mITT subjects results are presented.</description>
        <time_frame>1, 3, 6, 12, 18 and 24 months post index procedure</time_frame>
        <population>Post-Intervention Secondary Patency by Follow-Up Period (mITT Subjects). (n) varies in relation to the number of failures (access abandonment) recorded at 30 days, 90 days and 6 months. Accordingly, the (n) for each period may be different from the overall (N) reported in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-intervention Secondary Patency</title>
          <description>Secondary Patency is defined as the interval after the index intervention until the access is abandoned. Multiple repetitive treatments can be included in post-intervention secondary patency.&#xD;
Whereas the measure time frames for the overall study are 1, 3, 6, 12,18 and 24 months, the interim report only provides the 1, 3, and 6 months results. The 12,18 and 24 months results will be provided in the final reporting for the study.&#xD;
mITT subjects results are presented.</description>
          <population>Post-Intervention Secondary Patency by Follow-Up Period (mITT Subjects). (n) varies in relation to the number of failures (access abandonment) recorded at 30 days, 90 days and 6 months. Accordingly, the (n) for each period may be different from the overall (N) reported in the Participant Flow section.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with Secondary Patency at 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Secondary Patency at 90 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Secondary Patency at 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Secondary Patency at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Secondary Patency at 18 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Secondary Patency at 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Technical Success</title>
        <description>Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure. Therefore, for this measure, only COVERA data are relevant.&#xD;
mITT results are presented. Number of participants (n) included in this analysis is different from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
Technical success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
        <time_frame>On Day of Index Procedure</time_frame>
        <population>Number of Participants with Acute Technical Success (mITT Subjects). Please note that &quot;Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.&quot; Therefore, for this measure, only COVERA data are relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Technical Success</title>
          <description>Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure. Therefore, for this measure, only COVERA data are relevant.&#xD;
mITT results are presented. Number of participants (n) included in this analysis is different from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.&#xD;
Technical success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
          <population>Number of Participants with Acute Technical Success (mITT Subjects). Please note that &quot;Technical Success is defined as successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.&quot; Therefore, for this measure, only COVERA data are relevant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Procedure Success</title>
        <description>Procedure Success is defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis.&#xD;
Procedure success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
        <time_frame>On Day of Index Procedure</time_frame>
        <population>Procedure Success (mITT Subjects). Number of participants (n) included in this analysis is different from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Covera Vascular Covered Stent Following PTA</title>
            <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
          </group>
          <group group_id="O2">
            <title>PTA Only Using Uncoated PTA Balloon</title>
            <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedure Success</title>
          <description>Procedure Success is defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis.&#xD;
Procedure success was assessed on the day the index procedure was performed, which may be a different day for each participant.</description>
          <population>Procedure Success (mITT Subjects). Number of participants (n) included in this analysis is different from overall enrollment (N) as some subjects discontinued participation before the 30 days, 90 days and 6 months follow-up or did not meet endpoint inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data provided for Adverse Events (AEs) and Serious Adverse Events (SAEs) at 6-Month Follow-Up Period (ITT Subjects). All subjects underwent a clinical evaluation at the index procedure: treated subjects also underwent a follow-up clinical evaluation prior to hospital discharge. Subsequent follow-up for all treated subjects was performed at 30 days, 90 days and 6 months. The 6 month follow up was an office visit to the investigational site in addition to a telephone call to dialysis centre.</time_frame>
      <desc>Both AEs and SAEs were collected based on the ITT population. SAEs results shown are CEC adjudicated.&#xD;
Note that n= subjects with at least one event. AEs and SAEs that occurred through 180 days are included. AEs and SAEs in Tables below were reported in the CSR by Organ Class only, without regards to the specific Adverse Event Terms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Covera Vascular Covered Stent Following PTA</title>
          <description>Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)&#xD;
Covera Vascular Covered Stent following PTA: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.</description>
        </group>
        <group group_id="E2">
          <title>PTA Only Using Uncoated PTA Balloon</title>
          <description>Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon: Treatment of stenoses with PTA only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="142"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="142"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="142"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="142"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="142"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal and connective disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="142"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="142"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="142"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="142"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="142"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="142"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="142"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Electrocardiogram ST segment depression, liver function, abnormal and test abnormal, peritoneal effluent and troponin T increase.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="142"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal and connective tissues</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="142"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="142"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="142"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="142"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="142"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to PI publication of site results, sponsor requires publication of multi-centers results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Lam, Associate Project Manager, Clinical Affairs</name_or_title>
      <organization>BD/Bard</organization>
      <phone>(763) 390-8616</phone>
      <email>heather.lam@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

